Skip to main content
. 2019 Jan 18;8(2):814–823. doi: 10.1002/cam4.1952

Table 2.

The incident cases number and incidence rate of childhood cancer during 2010‐2014 in Henan Province, China

ICCC3 categorya Incident cases number Proportion (%) Age‐specific incidenceb Crude rate WSRc
0‐4 5‐9 10‐14 15‐19 0‐14 15‐19 0‐4 5‐9 10‐14 15‐19 0‐14 0‐19 0‐14 0‐19
I Leukemia 248 233 210 200 49.50 36.23 45.46 42.93 37.98 34.27 42.10 40.05 42.47 40.63
a. Lymphoid 52 40 48 49 10.03 8.88 9.53 7.37 8.68 8.40 8.53 8.50 8.59 8.54
b. Acute myeloid 19 30 8 18 4.08 3.26 3.48 5.53 1.45 3.08 3.47 3.37 3.55 3.45
c. CMD 2 2 1 3 0.36 0.54 0.37 0.37 0.18 0.51 0.30 0.36 0.31 0.36
d. MDS & other 7 15 8 13 2.15 2.36 1.28 2.76 1.45 2.23 1.83 1.93 1.81 1.90
e. Unspecified 168 146 145 117 32.88 21.20 30.79 26.90 26.22 20.05 27.97 25.89 28.21 26.37
II Lymphoma & related 15 22 23 26 4.30 4.71 2.75 4.05 4.16 4.46 3.66 3.87 3.58 3.78
a. Hodgkin 1 6 6 8 0.93 1.45 0.18 1.11 1.09 1.37 0.79 0.94 0.74 0.88
b. Non‐Hodgkin except BL 5 7 9 7 1.50 1.27 0.92 1.29 1.63 1.20 1.28 1.26 1.24 1.23
c. Burkitt (BL) 0 0 0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
d. Lymphoreticular 0 1 0 0 0.07 0.00 0.00 0.18 0.00 0.00 0.06 0.04 0.06 0.05
e. Unspecified 9 8 8 0 1.79 0.00 1.65 1.47 1.45 1.89 1.52 1.62 1.53 1.61
III CNS neoplasms 69 89 89 75 17.69 13.59 12.65 16.40 16.10 12.85 15.05 14.47 14.86 14.41
a. Ependymoma 0 0 0 1 0.00 0.18 0.00 0.00 0.00 0.17 0.00 0.04 0.00 0.04
b. Astrocytoma 5 13 7 7 1.79 1.27 0.92 2.40 1.27 1.20 1.52 1.44 1.49 1.43
c. CNS embryonal 0 4 3 0 0.50 0.00 0.00 0.74 0.54 0.00 0.43 0.31 0.40 0.31
d. Other gliomas 13 15 15 10 3.08 1.81 2.38 2.76 2.71 1.71 2.62 2.38 2.60 2.40
e. Other specified 4 6 8 6 1.29 1.09 0.73 1.11 1.45 1.03 1.10 1.08 1.06 1.05
f. Unspecified CNS 47 51 56 51 11.03 9.24 8.61 9.40 10.13 8.74 9.38 9.21 9.31 9.18
IV Neuroblastoma 3 0 2 0 0.36 0.00 0.55 0.00 0.36 0.00 0.30 0.22 0.32 0.25
a. (Ganglio)neuroblastoma 3 0 0 0 0.21 0.00 0.55 0.00 0.00 0.00 0.18 0.13 0.21 0.16
b. Peripheral nervous 0 0 2 0 0.14 0.00 0.00 0.18 0.00 0.00 0.79 0.09 0.11 0.08
V Retinoblastoma 12 1 0 0 0.93 0.00 2.20 0.18 0.00 0.00 0.79 0.58 0.91 0.71
VI Renal tumors 24 7 6 2 2.65 0.36 4.40 1.29 1.09 0.34 2.25 1.75 2.43 1.96
a. Nephroblastoma 11 5 0 0 1.15 0.00 2.02 0.92 0.00 0.00 0.97 0.72 1.08 0.84
b. Renal carcinoma 2 1 3 1 0.43 0.18 0.37 0.18 0.54 0.17 0.37 0.31 0.36 0.32
c. Unspecified 11 1 3 1 1.07 0.18 2.02 0.18 0.54 0.17 0.91 0.72 1.00 0.81
VII Hepatic tumors 6 1 5 16 0.86 2.90 1.10 0.18 0.90 2.74 0.73 1.26 0.75 1.20
a. Hepatoblastoma 5 0 0 0 0.36 0.00 0.92 0.00 0.00 0.00 0.30 0.22 0.35 0.27
b. Hepatic carcinoma 0 0 3 8 0.21 1.45 0.00 0.00 0.54 1.37 0.18 0.49 0.16 0.43
c. Unspecified 1 1 2 8 0.29 1.45 0.18 0.18 0.36 1.37 0.24 0.54 0.24 0.49
VIII Bone tumors 7 19 43 54 4.94 9.78 1.28 3.50 7.78 9.25 4.20 5.53 3.88 5.09
a. Osteosarcoma 0 5 20 19 1.79 3.44 0.00 0.92 3.62 3.26 1.52 1.98 1.35 1.78
b. Chondrosarcoma 0 0 5 9 0.36 1.63 0.00 0.00 0.90 1.54 0.30 0.63 0.26 0.55
c. Ewing & related 0 0 0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
d. Other specified 0 1 2 2 0.21 0.36 0.00 0.18 0.36 0.34 0.18 0.22 0.16 0.20
e. Unspecified 7 13 16 24 2.58 4.35 1.28 2.40 2.89 4.11 2.19 2.70 2.11 2.56
IX Soft tissue sarcoma 9 16 8 12 2.36 2.17 1.65 2.95 1.45 2.06 2.01 2.02 2.01 2.02
a. Rhabdomyosarcoma 1 2 1 0 0.29 0.00 0.18 0.37 0.18 0.00 0.24 0.18 0.24 0.19
b. Fibrosarcoma 0 1 0 0 0.07 0.00 0.00 0.18 0.00 0.00 0.06 0.04 0.06 0.05
c. Kaposi sarcoma 0 0 0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
d. Other specified 7 10 7 12 1.72 2.17 1.28 1.84 1.27 2.06 1.46 1.62 1.46 1.59
e. Unspecified 1 3 0 0 0.29 0.00 0.18 0.55 0.00 0.00 0.24 0.18 0.25 0.19
X Germ cell tumors 10 6 9 29 1.79 5.25 1.83 1.11 1.63 4.97 1.52 2.43 1.54 2.31
a. CNS germ cell 0 1 0 1 0.07 0.18 0.00 0.18 0.00 0.17 0.06 0.09 0.06 0.08
b. Other extragonadal 4 0 0 1 0.29 0.18 0.73 0.00 0.00 0.17 0.24 0.22 0.28 0.26
c. Gonadal germ cell 4 0 0 13 0.29 2.36 0.73 0.00 0.00 2.23 0.24 0.76 0.28 0.72
d. Gonadal carcinoma 1 3 7 8 0.79 1.45 0.18 0.55 1.27 1.37 0.67 0.85 0.62 0.79
e. Unspecified gonadal 1 2 2 6 0.36 1.09 0.18 0.37 0.36 1.03 0.30 0.49 0.29 0.46
XI Carcinoma & melanoma 18 26 30 72 5.30 13.04 3.30 4.79 5.43 12.34 4.51 6.56 4.40 6.18
a. Adrenocortical 2 1 0 0 0.21 0.00 0.37 0.18 0.00 0.00 0.18 0.13 0.20 0.16
b. Thyroid 0 4 4 12 0.57 2.17 0.00 0.74 0.72 2.06 0.49 0.90 0.45 0.81
c. Nasopharyngeal 0 0 1 3 0.07 0.54 0.00 0.00 0.18 0.51 0.06 0.18 0.05 0.16
d. Melanoma 14 5 2 5 1.50 0.91 2.57 0.92 0.36 0.86 1.28 1.17 1.40 1.27
e. Skin carcinoma 0 2 2 8 0.29 1.45 0.00 0.37 0.36 1.37 0.24 0.54 0.22 0.48
f. Other & unspecified 2 14 21 44 2.65 7.97 0.37 2.58 3.80 7.54 2.25 3.64 2.08 3.31
XII Other & unspecified 54 41 35 66 9.31 11.96 9.90 7.55 6.33 11.31 7.92 8.81 8.11 8.83
a. Other specified 0 0 0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
b. Other unspecified 54 41 35 66 9.31 11.96 9.90 7.55 6.33 11.31 7.92 8.81 8.11 8.83
Total 475 461 460 552 100.00 100.00 87.06 84.94 83.19 94.60 85.06 87.56 85.25 87.36
a

Childhood Cancer Categorized by International Classification of Childhood Cancer, Third Edition, ICCC3.

b

The age‐specific incidence (ASR) and crude rate were calculated by per million person‐years.

c

The age‐standardized rate was adjusted by World Segi's standardized population (WSR).